Cipla & Formosa Ink Licensing Deal for Clobetasol Suspension Kumar Jeetendra | March 18, 2025 Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals (6838.TW) for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007). Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain following ocular surgery across 11 countries …
Revolutionizing Infectious Disease: Dr. Paul’s Journey Kumar Jeetendra | May 12, 2025 In this captivating episode of our podcast series, we feature the world-renowned microbiologist, inventor, and thought leader in anti-infectives and infectious disease R&D, Dr. Maneesh Paul. Key Highlights: The story of Enmetazobactam – India’s first indigenously developed anti-infective and its journey from concept to global approvals (DCGI, USFDA, UKMHRA, EMA). Aspects of AMR, Planetary Health, …
